Novartis AG ADR (NVS)vsQiagen NV (QGEN)
NVS
Novartis AG ADR
$148.38
-0.55%
HEALTHCARE · Cap: $273.77B
QGEN
Qiagen NV
$36.68
-2.34%
HEALTHCARE · Cap: $7.64B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 2596% more annual revenue ($56.58B vs $2.10B). NVS leads profitability with a 23.9% profit margin vs 19.2%. QGEN appears more attractively valued with a PEG of 0.93. QGEN earns a higher WallStSmart Score of 61/100 (C+).
NVS
Hold49
out of 100
Grade: D+
QGEN
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Margin of Safety
-26.4%
Fair Value
$40.38
Current Price
$36.68
$3.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 23.8%
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
1.8% revenue growth
Earnings declined 23.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : QGEN
The strongest argument for QGEN centers on PEG Ratio, Price/Book, Operating Margin. Profitability is solid with margins at 19.2% and operating margin at 23.8%. PEG of 0.93 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : QGEN
The primary concerns for QGEN are Revenue Growth, EPS Growth.
Key Dynamics to Monitor
NVS profiles as a declining stock while QGEN is a value play — different risk/reward profiles.
QGEN carries more volatility with a beta of 0.66 — expect wider price swings.
QGEN is growing revenue faster at 1.8% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
QGEN scores higher overall (61/100 vs 49/100), backed by strong 19.2% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Qiagen NV
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
QIAGEN NV provides sample-to-knowledge solutions that transform biological materials into molecular knowledge globally. The company is headquartered in Venlo, the Netherlands.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?